Abstract
The staging system of head and neck cancer is a Tumor-Node-Metastases system that was developed by the American Joint Committee on Cancer. The stage of the head and neck cancer defines the extent of the lesion and is determined by physical examination, radiologic studies, and pathologic examination. Accurate staging of head and neck cancer is critical since it will determine the treatment modalities used to cure the disease. Recent advances in the field of molecular genetics have allowed clinicians to detect occult cancer cells previously missed by physical examination and standard histopathologic techniques. Molecular assays are 500 times more sensitive in identifying cancer cells than standard techniques and provide more objective analyses with fewer sampling errors. Consequently, these techniques are currently being used to perform molecular staging of head and neck cancer patients. Preliminary results show that molecular staging will accurately identify those patients at significantly increased risk for recurrence of their head and neck cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beahrs OH, Henson DE, Hutter RVP, Myers MH (eds): Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott: 27–62, 1988
Robbins KT: Neck dissection classification and TNM staging of head and neck cancer. American Academy of Otolaryngology-Head and Neck Surgery Foundation: 1–29, 1991
Thawley SE, Panje WR: Comprehensive management of head and neck tumors. Philadelphia: W.B. Saunders Company: 780, 1987
Biller HF, Davis WH, Ogura JH: Delayed contralateral cervical metastases with laryngeal and laryngopharyngeal cancers. Laryngoscope 81: 1499, 1971
Ogura JH, Biller HF, Wette R: Elective neck dissection for pharyngeal and laryngeal cancers: an evaluation. Ann Otol Rhinol Laryngol 80: 646, 1971
Brennan JA, Mao L, Hruban RH et al..: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Eng J Med 332: 429–435, 1995
Sidransky D, Von Eschenbach A, Tsai YC et al.: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706–709, 1991
Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846–847, 1992
Sidransky D, Tokino T, Hamilton SR et al.: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256: 102–105, 1992
Boyle J, Hakim J, Koch W et al.: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477–4480, 1993
Brennan JA, Boyle JO, Koch WM et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712–717, 1995
Thomas S, Brennan J, Martel G et al.: Mutations in the conserved regions of p53 are infrequent in betel-associated oral cancers from Papua New Guinea. Cancer Res 54: 3588–3593, 1994
Koch WM, Patel H, Brennan JA, Boyle JO, Sidransky D: Squamous cell carcinoma of the head and neck in the elderly. Arch Otolaryngol Head Neck Surg 121: 262–265, 1995
Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49–53, 1991
Mao L, Hruban RH, Boyle HO, Tockman M, Sidransky D: Detection of oncogene mutations in sputum precedes the diagnosis of lung cancer. Cancer Res 54: 1634–1637, 1994
Nowel PC: The clonal evolution of tumor cell populations. Science 194: 23–28, 1976
Weinberg RA: Tumor Suppressor Genes. Science 254: 1138–1146, 1991
Friedman T: Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70: 1810–1817, 1992
Weinberg RA: The integration of molecular genetics into cancer management. Cancer 70: 1653–1658, 1992
Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B: Clonal origin of bladder cancer. N Engl J Med 326: 737–740, 1992
Vogelstein B, Kinzler KW: Carcinogens leave fingerprints. Nature 355: 209–210, 1992
Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318–1327, 1993
Hunter T: Cooperation between oncogenes. Cell 64: 249–270, 1991
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759–767, 1990
Peto R, Roe FJ, Lee PN, Levy L, Clack J: Cancer and ageing in mice and man. Br J Cancer 32: 411–426, 1975
Dix D: The role of aging in cancer incidence: an epidemiological study. J Gerontol 44: 10–18, 1989
Puisieux A, Lim S, Groopman J, Ozturk M: Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 51: 6185–6189, 1991
Chung KY, Mukhopadhyay T, Kim J et al.: Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 53: 1676–1683, 1993
Baker SJ, Preisinger AC, Jessup JM et al.: p53 mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717–7722, 1990
Buchman GW, Schester DM, Raschtchas A: Rapid and efficent cloning of PCR products using the clone amp system. Focus 14: 41–45, 1992
Gusterson BA, Ramaswamy A, Warren W et al.: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6: 1785–1789, 1991
Sakai E, Tsuchida N: Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7: 927–933, 1992
Melhem MF, Law JC, el-Ashmawy L et al.: Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 146: 1170–1177, 1995
Xu L, Chen YT, Huvos AG, Zlotolow IM et al.: Overexpression of p53 protein in squamous cell carcinomas of the head and neck without apparent gene mutations. Diag Molec Pathol 3: 83–92, 1994
Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR: Problems with p53 immunohistochemical staining. Br J Cancer 69: 26–31, 1994
Wynford-Thomas D: p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166: 329–330, 1992
Brennan JA, Koch WM, Boyle JO et al.: Effect of p53 gene mutation on survival in head and neck squamous carcinoma. Submitted for publication, 1995
Yoo GH, Xu HJ, Brennan JA et al.: Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 54: 4603–4606, 1994
Nawroz H, van der Riet P, Koch W, Ruppert JM, Sidransky D: Allelotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152–1155, 1994
Kowalski LP, Magrin J, Waksman G et al.: Supraomohoyoid neck dissection in the treatment of head and neck tumors. Otolaryngol Head Neck Surg 119: 958–963, 1993
Soo KC, Spiro RH, King W, Harvey W, Strong EW: Squamous carcinoma of the gums. Am J Surg 156: 281–285, 1988
Fielding LP, Fenoglio-Preiser CM, Freedman LS: The future of prognostic factors in outcome prediction for patients with cancer. Cancer 70: 2367–2377, 1992
Ghouri AF, Zamora RL, Harvey JE, Spitznagel EL, Sessions DG: Epidermoid carcinoma of the oral cavity and oropharynx: validity of the current AJCC staging system and new statistical tools for the prediction of subclinical neck disease. Otolaryngol Head Neck Surg 108: 225–232, 1993
Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA: Prognostic factors of neck node metastasis. Clin Otolaryngol 7: 185–192, 1982
Boyle JO, Mao L, Brennan JA et al.: Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 168: 429–432, 1994
Koch WM, Boule JO, Mao L, Hakim J, Hruban RH, Sidransky D: p53 gene mutations as markers of tumor spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg 120: 943–947, 1994